Table 2 Clinical characteristics of the validation set
From: The signature of liver cancer in immune cells DNA methylation
Variable | Control (n = 10) | HepB (n = 10) | HepC (n = 10) | HCC1 (n = 8) | HCC2 (n = 12) | HCC3 (n = 11) | HCC4 (n = 19) | p value |
|---|---|---|---|---|---|---|---|---|
Age (mean ± SD) | 35.5 ± 7.5 | 43.9 ± 15.46 | 50.1 ± 14.7 | 61.75 ± 9.39 | 56 ± 7.45 | 48.09 ± 7.49 | 53.63 ± 9.77 | 5 × 10−5 |
Sex | Â | |||||||
 Male | 6 (60%) | 7 (70%) | 5 (50%) | 8 (100%) | 10 (83%) | 11 (100%) | 16 (84%) |  |
 Female | 4 | 3 | 5 | 0 | 2 | 0 | 3 |  |
Alcohol | 8 × 10−4 | |||||||
 No | NA | 10 (100%) | 9 (90%) | 7 (87.5%) | 8 (67%) | 3 (27%) | 9 (47%) |  |
 Quit | NA | 0 | 1 | 0 | 0 | 0 | 1 |  |
 Infrequent | NA | 0 | 0 | 0 | 1 | 0 | 0 |  |
 Heavy | NA | 0 | 0 | 1 | 3 | 8 | 9 |  |
Smoking | 0.035 | |||||||
 No | NA | 6 (60%) | 8 80%) | 4 (50%) | 8 (67%) | 9 (82%) | 9 (47%) |  |
 Quit | NA | 1 | 0 | 0 | 1 | 0 | 0 |  |
 Low | NA | 0 | 0 | 0 | 0 | 0 | 1 |  |
 Heavy | NA | 3 | 2 | 4 | 3 | 2 | 9 |  |
Cirrhosis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Â |
Hepatitis B | 0 (0%) | 10 (100%) | 1 (10%) | 8 (100%) | 12 (100%) | 11 (100%) | 19 (100%) | 3 × 10−13 |
Hepatitis C | 0 (0%) | 0 (0%) | 10 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 |
AFP | 0 (0%) | 0 (0%) | 0 (0%) | 1 (12.5%) | 2 (16.6%) | 4 (36%) | 9 (47.3%) | 0.34 |